Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akston, Brii, Eli Lilly, Humanigen, Immutep, Incyte, Jacobio, Kiniksa, Lumosa, Novavax, Pharmaxis, RDIF, Stemedica Cell Technologies, Takeda, Telix, Vanda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Ascletis, Astrazeneca, Beigene, China Oncology Focus, Clarity, Daewoong, Eccogene, Effector, Entasis, GNT Biotech & Medicals, Hutchmed, Kintor, Lee’s Pharmaceutical Holdings, Newsoara, Palisade, RDIF, Sorrento, Trevena, Zai Lab.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Acticor, Antengene, Bonus Biogroup, Frontier, Kyowa Kirin, Nrx, Ose Immunotherapeutics, Qilu, Redhill, Samsung Bioepis, Sesen, Sorrento, Takeda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Affinivax, Akeso, Ascletis, Asieris, Astellas, Bergenbio, Bionomics, Bio-Thera Solutions, Corvus, Cyxone, Ena Respiratory, Harbour Biomed, Immunovative Therapies, Mesoblast, Mirror Biologics, Nrx, Photocure, Quantum Leap Healthcare Collaborative, Recce, Transcenta.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aim Immunotech, Akston, Ascendis, Astrazeneca, Bharat Biotech, Clover, Daiichi Sankyo, Eiger, Epimab, Evgen, Gan and Lee, Hutchmed, Innate, Jiangsu Nhwa, Johnson & Johnson, Nrx, Ocugen, Oryzon Genomics, Rakuten Medical, Reithera, Takeda, Tetherex, Transcenta, Trevena, Zydus Cadila.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: ABL, Altimmune, Angion Biomedica, Astrazeneca, Atea, Bionet Asia, Biophytis, Brim, Codagenix, Curevac, Cynata, Ildong, I-Mab, LG Chem Life Sciences, Moderna, Neurophth, Nippon Shinyaku, Novavax, Pfizer, Pharmajet, RDIF, Rigel, Roche, Sinovac, Technovalia, VBI Vaccines.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aim Immunotech, Amerimmune, Ampio, Astrazeneca, Brickell, Cytodyn, Galecto, Hightide, Histogen, Immutep, Innovent, Kaken, Noveome, Partner, Redhill, Scancell, Shenzhen Kangtai Biological Products, Sorrento, Sosei, Telix, Theravance.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Abbvie, Anheart, Appili, Ashvattha, Astrazeneca, Beigene, Bridge, Curevac, Edesa, Gannex, Glaxosmithkline, Harbour Biomed, Innocare, Innovent Biologics, Jacobio, Kancera, Novavax, Nrx, Oncotelic, Organicell Regenerative Medicine, Pfizer, Regeneron, Vir, Xwpharma.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adamis, Astrazeneca, Azurrx, Bio-Thera Solutions, Celltrion, Daiichi Sankyo, Glenmark, Iaso, Icosavax, Immvira, Innovent, Kazia, Kyowa Kirin, Mei, Molecular Partners, Novavax, Redhill, Takeda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: 4D, AB Science, Advaccine, Biogen, Bio-Thera Solutions, Brickell, Bridge, Celltrion Healthcare, Curevac, Hightide, Innovation, Kaken, Neuren, Qbiotics, Transcenta, Valneva.